Structure Shares Phase 2b Aleniglipron Weight Loss Data

Oral small-molecule GLP-1 receptor agonists represent a potential shift in obesity treatment.

Obesity management is entering a new era with once-daily pills that could replace weekly injections. On June 5, 2026, Structure Therapeutics announced exciting results from its Phase 2b ACCESS clinical trial evaluating aleniglipron (formerly GSBR-1290). This experimental once-daily oral drug is a small-molecule GLP-1 receptor agonist—a type of medicine that mimics natural gut hormones to control appetite and blood sugar. Published in Nature Medicine and presented at the American Diabetes Association (ADA) 86th Scientific Sessions, the data shows that aleniglipron helps adults with overweight or obesity shed significant weight over 36 weeks.

The drug successfully met all primary and secondary endpoints in the trial. Lead author Dr. Julio Rosenstock highlighted that aleniglipron offers a highly effective, needle-free option for chronic weight management. Patients taking the daily pill achieved up to 11.3% placebo-adjusted weight loss at 36 weeks, with some reaching up to 16.2% weight loss in longer extension studies. With a Phase 3 program launching in the third quarter of 2026, this pill could soon become a major player in metabolic care.

What Is Aleniglipron and How Does It Work?

Aleniglipron is an experimental, daily pill designed to target the GLP-1 receptor, which plays a major role in how your body manages hunger and blood sugar. When you eat, your intestines naturally release the GLP-1 hormone to signal fullness to your brain, slow down digestion, and prompt your pancreas to release insulin. By mimicking this natural pathway, aleniglipron helps you feel full faster and stay full longer. This natural satiety response makes it much easier to reduce daily calories and achieve lasting weight loss.

Unlike traditional GLP-1 drugs like semaglutide and tirzepatide, which are peptide-based, aleniglipron is a small-molecule drug. Peptides are fragile chains of amino acids that your stomach acid easily breaks down, which is why most of these therapies must be injected. Even oral peptides require strict morning routines, forcing you to take them on an empty stomach with a tiny sip of water and wait at least 30 minutes to eat. For those exploring their current healthcare options, comparing new oral pipelines with established semaglutide treatment programs or tirzepatide options can help you make the best decision for your lifestyle.

Because aleniglipron is a chemically synthesized small molecule, it is far more stable in the stomach than peptide drugs. This means your body can absorb the pill easily without strict fasting rules or water limits. For patients, this translates to an incredibly convenient daily routine: a simple pill you can take anytime. This needle-free and hassle-free approach could make long-term weight management much easier to stick to.

What Were the Key Findings of the ACCESS Phase 2b Trial?

The Phase 2b ACCESS trial evaluated the safety and effectiveness of once-daily oral aleniglipron in 230 adults with obesity or overweight and at least one weight-related health issue. Researchers split participants into groups receiving a placebo or one of three daily doses: 45 mg, 90 mg, or 120 mg. The team tracked how much body weight patients lost over a 36-week period. This rigorous trial design helps ensure the results are reliable for patients seeking real solutions.

The published data in Nature Medicine shows that aleniglipron delivered impressive, dose-dependent weight loss across all three groups. At week 36, participants achieved these outstanding placebo-adjusted results:

• 45 mg Dose: Patients lost an average of 8.2% of their body weight.
• 90 mg Dose: Patients lost an average of 9.8% of their body weight.
• 120 mg Dose: Patients achieved a remarkable average weight loss of 11.3%.

These results demonstrate that increasing the daily dose of aleniglipron directly enhances weight loss outcomes. Furthermore, the trial showed that the highest dose helped the majority of patients achieve significant weight reduction milestones.

For patients, the real-world milestone success rates are even more encouraging. In the highest-dose group (120 mg), an outstanding 86% of patients lost at least 5% of their body weight. Additionally, 70% of patients achieved a weight loss of 10% or greater, and 38% shed 15% or more of their body weight. These milestones represent life-changing improvements in mobility, energy, and overall health.

Aleniglipron improved key heart health markers beyond just numbers on the scale. Patients showed measurable improvements in blood pressure, blood sugar levels, and cholesterol profiles. If you are comparing these health benefits with the costs of available treatments, you can view current pricing details to plan your budget. This helps you weigh the comprehensive metabolic benefits against existing therapeutic options.

How Does the Tolerability and Safety Profile of Aleniglipron Compare to Injectable Alternatives?

Staying on a weight loss therapy long-term requires a drug you can tolerate easily. The ACCESS trial reports that aleniglipron was generally well tolerated, with a safety profile similar to injectable GLP-1 drugs. While some patients experienced side effects like nausea, diarrhea, and vomiting, these issues were mostly mild to moderate. Crucially, these symptoms occurred mainly during the initial dose-increase phase and faded once patients stayed on a steady dose.

In the study, only 10.4% of participants stopped treatment early due to side effects. This rate is highly competitive, often matching or beating the drop-out rates seen with popular injections. The trial also monitored patients for liver issues or abnormal heart rhythms, which can sometimes affect small-molecule drug development. Fortunately, researchers confirmed no liver injury or heart rhythm problems in any of the patients taking aleniglipron.

To make the drug even easier on the stomach, researchers developed a slower dosing schedule. Starting at a low 2.5 mg dose and gradually increasing it reduced side effects, dropping long-term discontinuation rates to between 2.0% and 3.4%. This gentle ramp-up makes the journey much more comfortable for patients. If you want to explore standard options currently available, you can check if you qualify to speak with a licensed clinician.

What Did the Open-Label Extension and ACCESS II Studies Reveal About Long-Term Weight Loss?

Successful weight management is a lifelong journey, meaning your treatment needs to work over the long haul. To test aleniglipron's durability, researchers extended the trial to 56 weeks in an open-label extension study. They also launched a second trial called ACCESS II to explore the benefits of higher doses over 44 weeks. Both studies aimed to see if patients could continue to lose weight safely over time.

The results suggest that weight loss does not plateau early. Patients continuing on the 120 mg daily dose achieved an average weight loss of up to 16.2% at 56 weeks. This continuous downward trend shows that the daily pill keeps working to reduce weight over a full year of treatment. For patients, this represents a steady, reliable path toward a healthier weight.

The ACCESS II study also tested higher doses to see if they could accelerate results without causing extra side effects. Patients taking the 180 mg dose achieved an average weight loss of 16.3% at 44 weeks, while the 240 mg group achieved a 16.0% reduction. These numbers match or exceed the results typically expected from weekly weight-loss injections. Even at these higher doses, the drug remained manageable with no new safety concerns, proving its flexible dosing potential.

What Are the Next Development Steps and Phase 3 Plans for Aleniglipron?

Following these successful trials, Structure Therapeutics is moving aleniglipron into final-stage testing. The company is on track to launch a global Phase 3 clinical program in the third quarter of 2026. These large-scale, international studies will evaluate the pill's safety and effectiveness in thousands of patients. This is the final regulatory step required before the drug can be approved for public use.

The upcoming Phase 3 trials will test aleniglipron for both obesity and type 2 diabetes. Researchers will measure the drug's long-term safety for your heart and its ability to burn fat while preserving muscle. They will also confirm whether patients can take the pill without any food or water restrictions. If successful, aleniglipron could become a leading choice in the growing market of daily weight loss pills.

The published ACCESS trial results represent a massive milestone in weight loss science. If Phase 3 trials succeed, this daily pill will offer an accessible, needle-free alternative to traditional injections. Patients and healthcare providers will watch these studies closely as the drug moves toward FDA review. Ultimately, aleniglipron could redefine how we manage metabolic health and chronic weight loss.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.